36 -2 (40) 2022 — Nishanova D.F. — MANAGEMENT OF PATIENTS WITH DIABETES MELLITUS AND COVID-19

MANAGEMENT OF PATIENTS WITH DIABETES MELLITUS AND COVID-19

Nishanova D.F. Andijan State Medical Institute, Uzbekistan

Resume

This article systematizes information on the prevalence of diabetes mellitus in patients with coronavirus infection, the characteristics of the activation of viral mechanisms and cascades of pathological reactions in the body, the possibility of glucose control in the background of COVID-19.

Keywords: COVID-19, diabetes mellitus, coronavirus infection.

First page

187

Last page

194

 For citation: Nishanova D.F. MANAGEMENT OF PATIENTS WITH DIABETES MELLITUS AND COVID-19 //New Day in Medicine 2(40)2022 187-194 https://cutt.ly/pAQ8Y38

 LIST OF REFERENCES:

  1. Clerkin K.J., Fried J.A., Raikhelkar J. et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation. 2020; 141(20): 1648–55.
  2. Zhu L., She Z.G., Cheng X. et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020; 31(6): 1068–77.e3.
  3. Roncon L., Zuin M., Rigatelli G. et al. Diabetic patients with COVID- 19 infection are at higher risk of ICU admission and poor short- term outcome. J. Clin. Virol. 2020; 127: 104354.
  4. Richardson S., Hirsch J.S., Narasimhan M. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020; 323(20): 2052–9.
  5. Jeong I.-K., Yoon K.H., Lee M.K. Diabetes and COVID-19: global and regional perspectives. Diabetes Res. Clin. Pract. 2020; 166: 108303.
  6. Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. Lancet. 2020; 395(10223): 497–506.
  7. Suleyman G., Fadel R.A., Malette K.M. et al. Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan Detroit. JAMA Netw. Open. 2020; 3(6): e2012270.
  8. Guo W., Li M., Dong Y. et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab. Res. Rev. 2020: e3319.
  9. Singh A.K., Gupta R., Ghosh A. et al. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab. Syndr. 2020; 14(4): 303–10.
  10. Sardu C., D’Onofrio N., Balestrieri M.L. et al. Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control? Diabetes Care. 2020; 43(7): 1408–15.
  11. Bode B., Garrett V., Messler J. et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J. Diabetes Sci. Technol. 2020; 14(4): 813–21.
  12. Goyal A., Gupta S., Gupta Y. et al. Proposed guidelines for screening of hyperglycemia in patients hospitalized with COVID-19 in low resource settings. Diabetes Metab. Syndr. 2020; 14(5): 753–6.
  13. Li J., Wang X., Chen J. et al. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes. Metab. 2020; 22(10): 1935–41.
  14. Chen Y., Yang D., Cheng B. et al. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose- lowering medication. Diabetes Care. 2020; 43(7): 1399–407.
  15. Cure E., Cumhur Cure M. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis. Diabetes Metab. Syndr. 2020; 14(4): 405–6.
  16. Авдеев С.Н., Адамян Л.В., Алексеева Е.И. и др. Вақтинчалик услубий қўлланма «Янги коронавирус инфекциясини (COVID-19) профилактика, диагностика ва даволаш» 08.02.2021 й.
  17. Feldman E.L., Savelieff M.G., Hayek S.S. et al. COVID-19 and diabetes: a collision and collusion of two diseases. Diabetes. 2020; 69(12): 2549–65.

file

download